Stockreport

Relmada Therapeutics Initiates Phase 1 Dosing with REL-P11 for Metabolic Disease

Relmada Therapeutics, Inc.  (RLMD) 
NASDAQ:AMEX Investor Relations: ir.relmada.com
PDF REL-P11 is a proprietary, low-dose, modified-release psilocybin formulation Single-Ascending Dosing (SAD) study to evaluate safety and pharmacokinetics in obese and nor [Read more]